Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Payments Still “Excessive” For Albuterol And Ipatropium, IG Says

Executive Summary

The HHS Inspector General is recommending significant further cuts in reimbursement for albuterol and ipatropium bromide under Medicare Part B

You may also be interested in...

Medicaid Reform Next On Health Care Agenda: GAO To Assess Rebates

The House Energy & Commerce/Oversight Subcommittee is directing the General Accounting Office to review Medicaid reimbursement policies in preparation for debate over reforms to the program

Average Sales Price Reports To Medicare From Rx Manufacturers Due April 30

Drug manufacturers' first quarter average sales price reports are due to the Centers for Medicare & Medicaid Services April 30

J&J Procrit Medicare Reimbursement Will Be 87% Of AWP Under Final Rule

Johnson & Johnson's Procrit will be reimbursed at 87% of average wholesale price under Medicare Part B in 2004, two percentage points higher than most drugs

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts